Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in Japanese patients with type 2 diabetes mellitus
NCT03322631Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2017
- Primary completion
- May 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Tirzepatide with Placebo (2 arms). Primary endpoint: Serious Adverse Events Related to Study Drug at 85 days. Started Nov 2017; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03322631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03322631.